Twenty years ago, many brands learned an expensive lesson from the low-carb boom. Companies rushed to reformulate products, investing in new recipes, manufacturing lines, and packaging. But that trend inevitably cooled.
The popularity of GLP-1 prescription medications for weight loss presents brands with a similar decision on how to adapt to shrinking consumer appetites and changing shopping baskets. The underlying consumer shift looks much more significant, but I think one of the biggest mistakes brands can make right now is assuming this moment automatically requires product innovation.
What GLP-1s have changed
Our Ideally research surveyed a nationally representative study of 2,184 U.S. adults and found that 10.4% of Americans currently take a GLP-1. When you include former users, people considering treatment, and people who live or socialize with someone taking the medication, nearly 60% of Americans now sit inside the broader GLP-1 footprint.
We found that one in seven Americans now lives with a GLP-1 user. In those households, the behaviors associated with the medication are already spreading. They’re more likely to do the following than people with no exposure to GLP-1s, including:
- More likely to buy high-protein foods
- Eat more protein
- Cook at home
- Drink less alcohol
- Notice smaller portion sizes among the people around them.
That signals a shift in consumer behavior. And the shift becomes even clearer when you look inside the basket.
What’s in the basket now
More than half of current GLP-1 users say they feel full on much smaller amounts, including the 42% who say they’ve lost interest in foods they used to love. The same percentage say they think about food less often.
That has real consequences for categories built around appetite and impulse. Among users:
- 44% say they’re buying less fast food at restaurants
- 39% are buying fewer sweet snacks
- 36% are buying less chocolate, candy, and confectionery
- 23% are buying fewer salty snacks.
Consumers are replacing these items in their baskets, with 40% reporting buying more fresh fruits and vegetables and around 3 in 10 buying more bottled water and high-protein snacks. Electrolyte drinks, zero-sugar beverages, gut-health products, and meal replacements are also gaining new fans.
Protein, in particular, is becoming a new kind of value signal. When you have less appetite to spend, every bite has to work harder. The product needs to feel satisfying, functional, or worth the space it takes up.
A longer-term shift in behaviors and spend
Behavior changes may be more durable than the prescription itself. Our study found that 8% of U.S. adults had previously taken a GLP-1 and stopped.
Yet among former users, a third still report feeling full on smaller portions, a third still experience reduced food noise, and around a fourth report lower interest in alcohol, roughly in line with current users.
Even within households containing GLP-1 users, the research shows people are adopting behaviors like buying high-protein versions and eating less sugar without necessarily taking the medication themselves.
So stopping the medication doesn’t necessarily mean snapping back to the old consumer behavior, which presents a very different challenge for brands. How do you respond to a much larger audience learning a different relationship with food: smaller portions, fewer impulse purchases, and a higher bar for what earns a place in the basket?
You can see that selectivity in spending. Of GLP-1 users, 38% say their total food and drink spending has decreased since starting the medication.
Another 40% say they’re spending about the same. Spending is moving toward replacement basket categories mentioned earlier, including produce, water, protein, and other products perceived as delivering greater value for a smaller appetite. The basket is increasingly harder to get into.
Innovate or reframe?
The instinctive response to changing consumer behavior is to create a product specifically for the GLP-1 consumer, whether adding protein, reducing sugar, or developing a smaller format.
But it’s also an expensive answer to arrive at before you’ve asked a much cheaper question: Does the product actually need to change, or does the story around it? The opportunity may be to give consumers a new reason to choose what you already sell.
Many of the products consumers are moving toward already exist now, including high-protein yogurt, smaller portions, and products built around satiety, hydration, and functional nutrition.
That should change the order of operations for brands. Before changing the formulation, test the positioning. Before rebuilding the product, test the occasions where and when people reach for it. Before investing in a new manufacturing process, find out whether consumers see fresh relevance in your product.
Modern consumer research can now test whether an existing product appeals, rather than spending a year creating a new one that does. We can understand whether consumers respond to smaller portions, protein, satiety, functionality, or value. We can test packaging, claims, messaging, and occasions quickly enough to distinguish a positioning problem from a product problem.
That sequence matters: Research first. Reposition second. Reformulate when the evidence tells you to.
The GLP-1 era is changing what people feel is worth eating, and moving beyond current users into households, social circles, and even former users.
Consumer behavior will almost always move faster than your innovation pipeline. The advantage is in identifying what changed, understanding why, and figuring out whether the product you need to win tomorrow is already sitting on your shelf today.
Joshua Nu’u-Steele is the cofounder and chief revenue officer of Ideally.